Skip to Main Content

An Observational Study of Patients Undergoing Therapy for Chronic Hepatitis B (HBV) Infection

  • Study HIC#:2000024189
  • Last Updated:07/15/2021

Brief Summary:

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of therapeutic outcomes for patients with chronic hepatitis B (HBV) who are currently taking tenofovir alafenamide (TAF) relative to those patients following other treatment regimens. The study will address important clinical questions regarding the management of HBV with TAF and other oral therapies by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to TAF.

  • Age18 years and older
  • GenderBoth
  • Start Date01/31/2019
  • End Date01/31/2020

Trial Purpose and Description

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of therapeutic outcomes for patients with chronic hepatitis B (HBV) who are currently taking tenofovir alafenamide (TAF) relative to those patients following other treatment regimens. The study will address important clinical questions regarding the management of HBV with TAF and other oral therapies by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to TAF.

Eligibility Criteria

Inclusion Criteria:

  • Male or female patients, age ≥18 years
  • On a stable antiviral therapy regimen for hepatitis B as determined by treating physician

Exclusion

  • Inability to provide written informed consent/assent
  • Known coinfection with hepatitis Delta
  • Known history of Human Immunodeficiency Virus (HIV)

For more information about this study, contact:

Or contact the Help us Discover team on: